Abstract | UNLABELLED: MATERIAL AND METHODS: The study group was 7 patients (hemodialysed--2 boys, mean age 7, 7+/-0.1; peritoneal dialysis--5: 3 boys and 2 girls, mean age 5, 6+/-5.0). Sevelamer ( Renagel, 800 mg, Genzyme) was used in all patients in mean dosis of 117 mg/kgm.c./d due to lack of effect of the typical treatment ( vitamin D, diet, calcium carbonate). Results of treatment by sevelamer were estimated by measuring of calcium, phosphates, albumins, parathormone and alkalic phosphate concentration in the serum and blood gases after 6 and 12 month. RESULTS: There were found that sevelamer treatment significantly decrease the phosphates concentration and CaxP product in the serum without influence on concentration of PTH or calcium. Any adverse events were observed during the study and any drug intolerance. CONCLUSION:
|
Authors | Dariusz Runowski, Bozena Jachimiak, Anna Cieślak-Puchalska, Beata Pacanowska, Tomasz Zimoń |
Journal | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
(Pol Merkur Lekarski)
Vol. 26
Issue 154
Pg. 318-21
(Apr 2009)
ISSN: 1426-9686 [Print] Poland |
Vernacular Title | Zastosowanie sewelameru w leczeniu opornej hiperfosfatemii u dzieci z przewlekła niewydolnościa nerek. |
PMID | 19580197
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Chelating Agents
- Polyamines
- Sevelamer
|
Topics |
- Chelating Agents
(therapeutic use)
- Child
- Child, Preschool
- Drug Resistance
- Female
- Humans
- Hyperphosphatemia
(drug therapy, etiology)
- Kidney Failure, Chronic
(complications, therapy)
- Male
- Peritoneal Dialysis
(adverse effects)
- Polyamines
(therapeutic use)
- Renal Dialysis
(adverse effects)
- Sevelamer
- Treatment Outcome
|